Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV (Nearly Naive)

This study has been completed.
Sponsor:
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
AIDS Clinical Trials Group
ClinicalTrials.gov Identifier:
NCT00442962
First received: March 2, 2007
Last updated: June 1, 2015
Last verified: June 2015
Results First Received: July 13, 2011  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: HIV Infections
Interventions: Drug: Efavirenz
Drug: Emtricitabine/Tenofovir disoproxil fumarate

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Study participants were recruited at 8 sites from 3 countries: 6 in the US, 1 in Brazil, 1 in Peru, between May 2007 to December 2009.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
HIV-infected women, at least 16 years of age, whose only prior exposure to anti-retrovirals (ARVs) was for the purpose of prevention of mother-to-child transmission, who now qualify to start ARVs for their own health.

Reporting Groups
  Description
EFV + FTC/TDF Participants will take a daily regimen of efavirenz and emtricitabine/tenofovir disoproxil fumarate for 48 weeks

Participant Flow:   Overall Study
    EFV + FTC/TDF
STARTED   54 
Primary Outcome Evaluation   52 [1] 
COMPLETED   46 [2] 
NOT COMPLETED   8 
Pregnancy                1 
Lost to Follow-up                7 
[1] Primary outcome evaluation at week 24.
[2] Completed 48 weeks of follow-up.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
EFV + FTC/TDF Participants will take a daily regimen of efavirenz and emtricitabine/tenofovir disoproxil fumarate for 48 weeks

Baseline Measures
   EFV + FTC/TDF 
Overall Participants Analyzed 
[Units: Participants]
 54 
Age 
[Units: Years]
Mean (Standard Deviation)
 29  (7) 
Age, Customized 
[Units: Participants]
 
Between 19 and 25 years   19 
Between 26 and 30 years   16 
Between 31 and 35 years   9 
Between 36 and 40 years   6 
Between 40 and 45 years   4 
Gender 
[Units: Participants]
 
Female   54 
Male   0 
Region of Enrollment 
[Units: Participants]
 
United States   12 
Brazil   22 
Peru   20 
CD4 count, Continuous 
[Units: Cells/mm^3]
Mean (Standard Deviation)
 264  (104) 
CD4 count, Categorical 
[Units: Participants]
 
< 50 cells/mm^3   1 
Between 50 and 99 cells/mm^3   0 
Between 100 and 199 cells/mm^3   15 
Between 200 and 299 cells/mm^3   18 
Between 300 and 399 cells/mm^3   15 
400 or more cells/mm^3   5 
Plasma HIV-1 RNA, Continuous 
[Units: Log10 copies/mL]
Mean (Standard Deviation)
 4.5  (0.6) 
Plasma HIV-1 RNA, Categorical 
[Units: Participants]
 
<= 400 copies/mL   0 
Between 401 and 1000 copies/mL   1 
Between 1001 and 10,000 copies/mL   8 
Between 10,001 and 50,000 copies/mL   20 
Between 50,001 and 75,000 copies/mL   11 
Between 75,001 and 250,000 copies/mL   12 
More than 250,000 copies/mL   2 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants With Early Virologic Response   [ Time Frame: At Week 24 ]

2.  Secondary:   Time to First Safety Event   [ Time Frame: Throughout study ]

3.  Secondary:   Percentage of Participants With Early Virologic Suppression   [ Time Frame: At Weeks 24 ]

4.  Secondary:   Percentage of Participants With Late Virologic Response   [ Time Frame: At Week 48 ]

5.  Secondary:   Time to Initial Virologic Response   [ Time Frame: Throughout study ]

6.  Secondary:   Time to Initial Virological Failure   [ Time Frame: Throughout study ]

7.  Secondary:   Time to Loss of Virologic Response by Week 48 (Defined by FDA TLOVR Algorithm)   [ Time Frame: Throughout study ]

8.  Secondary:   Early Changes in CD4 Count From Baseline   [ Time Frame: At weeks 0(baseline), 4, 8, 16, 24 ]

9.  Secondary:   Percentage of Participants With Late Virologic Suppression   [ Time Frame: At Week 48 ]

10.  Secondary:   Time to First Dose Modification   [ Time Frame: Throughout study ]

11.  Secondary:   Late Change in CD4 Count From Baseline   [ Time Frame: At week 48 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Clinicaltrials.gov Coordinator
Organization: Center for Biostatistics in AIDS Research, Harvard School of Public Health
phone: 617-432-2829
e-mail: CBAR.ClinicalTrials.Gov@sdac.harvard.edu


Publications:

Responsible Party: AIDS Clinical Trials Group
ClinicalTrials.gov Identifier: NCT00442962     History of Changes
Other Study ID Numbers: ACTG A5227
1U01AI068636 ( US NIH Grant/Contract Award Number )
Study First Received: March 2, 2007
Results First Received: July 13, 2011
Last Updated: June 1, 2015
Health Authority: United States: Federal Government